GB202011142D0 - Use of cannabidiol in the treatment of seizures associated with brain damage - Google Patents

Use of cannabidiol in the treatment of seizures associated with brain damage

Info

Publication number
GB202011142D0
GB202011142D0 GBGB2011142.3A GB202011142A GB202011142D0 GB 202011142 D0 GB202011142 D0 GB 202011142D0 GB 202011142 A GB202011142 A GB 202011142A GB 202011142 D0 GB202011142 D0 GB 202011142D0
Authority
GB
United Kingdom
Prior art keywords
cannabidiol
treatment
brain damage
seizures associated
seizures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2011142.3A
Other versions
GB2597298A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Research Ltd
Original Assignee
GW Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Research Ltd filed Critical GW Research Ltd
Priority to GB2011142.3A priority Critical patent/GB2597298A/en
Publication of GB202011142D0 publication Critical patent/GB202011142D0/en
Priority to PCT/EP2021/069814 priority patent/WO2022017915A1/en
Publication of GB2597298A publication Critical patent/GB2597298A/en
Pending legal-status Critical Current

Links

GB2011142.3A 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with brain damage Pending GB2597298A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB2011142.3A GB2597298A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with brain damage
PCT/EP2021/069814 WO2022017915A1 (en) 2020-07-20 2021-07-15 Cannabidiol for use in the treatment of seizures associated with brain damage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2011142.3A GB2597298A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with brain damage

Publications (2)

Publication Number Publication Date
GB202011142D0 true GB202011142D0 (en) 2020-09-02
GB2597298A GB2597298A (en) 2022-01-26

Family

ID=72339054

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2011142.3A Pending GB2597298A (en) 2020-07-20 2020-07-20 Use of cannabidiol in the treatment of seizures associated with brain damage

Country Status (2)

Country Link
GB (1) GB2597298A (en)
WO (1) WO2022017915A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations

Also Published As

Publication number Publication date
WO2022017915A1 (en) 2022-01-27
GB2597298A (en) 2022-01-26

Similar Documents

Publication Publication Date Title
IL276217A (en) Use of cannabinoids in the treatment of epilepsy
IL285662A (en) Use of cannabinoids in the treatment of epilepsy
IL283372A (en) Use of cannabinoids in the treatment of epilepsy
GB2568809B (en) Use of cannabinoids in the treatment of epilepsy
GB2568471B (en) Use of cannabinoids in the treatment of epilepsy
IL274769A (en) Use of cannabinoids in the treatment of epilepsy
IL284758A (en) Use of cannabinoids in the treatment of comorbidities associated with epilepsy
GB201907283D0 (en) Use of cannabidiol in the treatment of epileptic spams
GB202019301D0 (en) Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes
GB2590793B (en) Cannabidiol-C1 for use as a medicament and in the treatment of epilepsy
GB202014723D0 (en) Use of cannabinoids in the treatment of epilepsy
GB202011123D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
GB202011155D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB201915522D0 (en) Use of cannabidiol preparations in the treatment of absence epilepsy
GB202011164D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy sydromes related to genetic abnormalities
EP3302464A4 (en) Use of cannabinoids in the treatment of ocular inflammation and/or pain
GB202011120D0 (en) Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB201915519D0 (en) Use of cannabidiol preparations in the treatment of temporal lobe epilepsy
GB202011142D0 (en) Use of cannabidiol in the treatment of seizures associated with brain damage
GB202102010D0 (en) Use of cannabidivarin in the treatment of seizures associated with canine epilepsy
GB202011154D0 (en) Use of cannabidiol in the treatment of seizures associated with encephaltis
GB202011126D0 (en) Use of cannabidiol in the treatment of sezures associated with mutifocal epilepsy
GB202011149D0 (en) Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage
GB202108690D0 (en) Use of cannabinoids in the treatment of epilepsy
GB202011139D0 (en) Use of cannabidiol, in the treatment of seizures associated with rare epilepsy sundromes